Cardiovascular Devices
This article was originally published in Start Up
Executive Summary
For all the attention given to cardiovascular disease, it still remains an unmet medical need. Now, a new crop of start-ups tries to improve the mortality rates for heart disease.
You may also be interested in...
AHA Wrap-Up: Studies Emphasize Improved Outcomes, Cost Effectiveness
Cardiovascular investigators are now asking new questions, including how can treatment be targeted to those most likely to benefit, and when does aggressive treatment become too much? At the 2006 American Heart Association (AHA) meeting, these questions were at the top of everyone's list, and several highly anticipated studies attempted to provide some answers.
World Congress of Cardiology: DES Safety Dominates Discussions
While the greater efficacy of drug-eluting stents (DES) compared to bare-metal stents is widely accepted, over the past year, data has continued to build showing that first-generation DES also have a higher late-stage in-stent thrombosis risk, a complication that can cause death 30% of the time, according to some estimates. The findings of these studies had some physicians at this year's World Congress of Cardiology calling for "an immediate halt to DES overuse." However, most conceded that additional randomized trials will be needed to fully understand the potential risks associated with these devices.
Hearten Medical Inc.
Hearten Medical Inc. has designed a less-invasive surgical system for repairing cardiac damage caused by heart attacks. The MyoTech Cardiac Restoration System applies heat to the external surface of a beating heart to shrink scar tissue and restore the heart to normal size and function.